Randomized phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: The CLEOPATRA Trial

BACKGROUND: Treatment standard for patients with primary glioblastoma (GBM) is combined radiochemotherapy with temozolomide (TMZ). Radiation is delivered up to a total dose of 60 Gy using photons. Using this treatment regimen, overall survival could be extended significantly however, median overall...

Descripción completa

Detalles Bibliográficos
Autores principales: Combs, Stephanie E, Kieser, Meinhard, Rieken, Stefan, Habermehl, Daniel, Jäkel, Oliver, Haberer, Thomas, Nikoghosyan, Anna, Haselmann, Renate, Unterberg, Andreas, Wick, Wolfgang, Debus, Jürgen
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2944178/
https://www.ncbi.nlm.nih.gov/pubmed/20819220
http://dx.doi.org/10.1186/1471-2407-10-478

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2944178/
https://www.ncbi.nlm.nih.gov/pubmed/20819220
http://dx.doi.org/10.1186/1471-2407-10-478

Ejemplares similares